Scientists at the University of Leicester have captured the first detailed “molecular movie” showing DNA being unzipped at the atomic level – revealing how cells begin the crucial process of copying their genetic material.

Since 2021, when lung cancer screening guidelines began to include younger people and those with a lower smoking history, the number of screenings climbed, but significant gaps remain, especially among people with limited access to healthcare, according to a new study led by researchers at Sylvester Comprehensive Cancer Center.

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and significantly reduced the risk of HCV-related hepatocellular carcinoma (HCC) after achieving sustained virologic response. However, the risk of HCC persists, particularly in patients with pre-treatment cirrhosis or fibrosis stage 3 (F3), even after DAA-induced viral eradication. While professional guidelines agree on the need for surveillance in cirrhotic patients, there is no consensus regarding surveillance for the pre-treatment F3 population following HCV eradication. The risk of HCC in the F3 population falls below the threshold for cost-effective surveillance. However, co-existing risk factors—such as diabetes, hepatic steatosis, alcohol use, advanced age, and elevated alpha-fetoprotein levels—may warrant reconsideration of HCC surveillance in this group. This underscores the need for an individualized, risk-based approach to HCC surveillance. This review provided a simplified algorithm to assist clinicians in managing patients with HCV after DAA-induced sustained virologic response.

Several polyoxometalates (POMs) have been shown to possess antitumor activity. In this study, hydrophilic POMs were combined with the hydrophobic drug podophyllotoxin (PPT) to create an amphiphilic anti-cancer drug PPT-POM-PPT, which can self-assemble into hollow vesicles. The properties of these vesicles, such as the critical aggregation concentration, were characterized. These vesicles had low hemolytic activity and high stability. Cytotoxicity tests showed that the PTT-POM-PPT vesicles exhibit strong antitumor activity against lung and liver cancer cells without significantly affecting normal cells. Cell uptake experiments confirm that the PPT-POM-PPT vesicles can easily penetrate cell membranes and effectively enter tumor cells, thus exerting anti-tumor effects. Furthermore, these vesicles co-localized with lysosomes. Moreover, these PPT-POM-PPT vesicles exhibit synergistic effects of PPT and POMs. They are efficient drug delivery platforms that act as both the carrier and the active drug, avoiding the potential risks associated with additional carrier ingredients. In summary, due to their anticancer properties, POMs and PPT facilitate the generation of novel amphiphilic self-assembling vesicles, providing a theoretical basis and enabling clinical applications of POMs in cancer therapy.